Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels
Internal Medicine Journal · 2024
DOI: 10.1111/imj.16105 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Kathryn Gazelakis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Alfred Health and Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Tumor Necrosis Factor Inhibitors, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Background
Inflammatory bowel disease (IBD) therapies now utilise higher doses of immunomodulatory and biologic therapies, predisposing patients to an increased risk of infections.
Aims
We aimed to determine whether infections were associated with high anti‐tumour necrosis factor (TNF) drug levels in IBD and to quantify the risk and consequences of infections.
Methods
Two retrospective studies were performed, a descriptive cohort study and a matched case–control study. For the matched case–control study, cases of infection occurring on anti‐TNF agents were matched in a 1:2 ratio to controls of anti‐TNF treated patients without infections.
Results
In the descriptive study, 76 infections occurred in 60 patients, including 49 bacterial, 24 viral, four fungal and four parasitic. Of these, 61 (80.3%) were on biologics, 49 (64.5%) on immunomodulators and 11 (14.5%) on corticosteroids. Thirty‐four (44.7%) were on combination therapy, 27 (35.5%) on biologic monotherapy and 15 (19.7%) on immunomodulator monotherapy. Median anti‐TNF drug levels in infection cases were 3.9 μg/mL for infliximab and 6.0 μg/mL for adalimumab. In the case–control study, 32 cases of infection in 27 anti‐TNF treated patients were matched with 64 anti‐TNF treated controls without infections. Among infection cases, 59.5% were on combination therapy versus 40.6% on biologic monotherapy ( P = 0.59). Median drug levels for cases and controls respectively were 3.9 μg/mL versus 5.5 μg/mL for infliximab ( P = 0.72) and 6.0 μg/mL versus 9.9 μg/mL for adalimumab ( P = 0.34).
Conclusion
Infections in patients with IBD were common, and the risk was highest with combination therapy. Infections were not associated with high serum anti‐TNF levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Alfred Health and Monash University, Melbourne, Victoria, Australia.
- Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Melbourne, Victoria, Australia.
- Data Science and AI Platform, Monash e-Research Centre, Melbourne, Victoria, Australia.
ORCID-Profile: Kathryn Gazelakis, Miles P Sparrow
Zitieren
APA
Gazelakis, K., Chu, I., Martin, C., & Sparrow, M. P. (2024). Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels. Internal Medicine Journal. https://doi.org/10.1111/imj.16105
Vancouver
Gazelakis K, Chu I, Martin C, Sparrow MP. Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels. Internal Medicine Journal. 2024. doi:10.1111/imj.16105
BibTeX
@article{Gazelakis2024,
author = {Gazelakis, Kathryn and Chu, Isabel and Martin, Catherine and Sparrow, Miles P},
title = {Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels},
journal = {Internal Medicine Journal},
year = {2024},
doi = {10.1111/imj.16105}
}
EUVIMED